NEW BRUNSWICK, N.J.,
Dec. 13, 2016 /PRNewswire/
-- Johnson & Johnson (NYSE: JNJ) today confirmed it has
ended discussions with Actelion Pharmaceuticals Ltd. (SIX: ATLN)
regarding a potential transaction. Johnson & Johnson was not
able to reach an agreement that it believed would create adequate
value for its shareholders.
About Johnson & Johnson
Caring for the
world, one person at a time, inspires and unites the people of
Johnson & Johnson. We embrace research and science - bringing
innovative ideas, products and services to advance the health and
well-being of people. Our approximately 126,900 employees at more
than 250 Johnson & Johnson operating companies work with
partners in health care to touch the lives of over a billion people
every day, throughout the world.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING
STATEMENTS
This communication contains "forward-looking statements" as
defined in the U.S. Private Securities Litigation Reform Act of
1995. The reader is cautioned not to rely on these forward-looking
statements. These statements are based on current expectations of
future events. If underlying assumptions prove inaccurate or known
or unknown risks or uncertainties materialize, actual results could
vary materially from the expectations and projections of Johnson
& Johnson. Risks and uncertainties include, but are not limited
to: the possibility that a potential transaction involving Actelion
will not be entered into or completed; if a transaction is entered
into, the terms and conditions of any such transaction; and whether
the potential benefits of any transaction would be realized. In
addition, if and when any transaction is consummated, there will be
risks and uncertainties related to the ability of the Johnson &
Johnson Family of Companies to successfully integrate the products
and employees of Actelion, as well as the ability to ensure
continued performance or market growth of its products. A further
list and description of the risks, uncertainties and other factors
related to the Johnson & Johnson Family of Companies can be
found in Johnson & Johnson's Annual Report on Form 10-K for the
fiscal year ended January 3, 2016,
including in Exhibit 99 thereto, and Johnson & Johnson's
subsequent filings. Copies of these filings are available online at
www.sec.gov, www.investor.jnj.com, or on request from Johnson &
Johnson. Johnson & Johnson does not undertake to
update any forward looking statement as a result of new information
or future events or developments.
This communication does not constitute, or form part of, any
offer or invitation to sell or issue, or any solicitation of any
offer, to purchase or subscribe for any registered shares in
Actelion, or Actelion's ADSs, nor shall it form the basis of, or be
relied on in connection with, any contract there for. There are no
assurances that a transaction will be reached or on what
terms.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/johnson--johnson-announces-it-has-ended-discussions-with-actelion-300377721.html
SOURCE Johnson & Johnson